Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $48
How Trial Wins And Drug Launch Revenue Will Impact Roivant Sciences Stock (ROIV)
Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology
Roivant Sciences Ltd (ROIV) (Q2 2026) Earnings Call Highlights: LISRIA Launch Delivers $31 ...
HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $48
Roivant Sciences (ROIV) Q2 2026 Earnings Call Transcript
Roivant Sciences Q2 Earnings Call Highlights
Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update
Roivant Sciences Ltd. 2026 Q2 - Results - Earnings Call Presentation
Roivant Sciences Q2 2027 Earnings Call Transcript
Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years
Roivant Sciences (ROIV) Stock Looks Expensive Against Its Book Value
Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift
Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $56
If You Invested $100 In Roivant Sciences Stock 5 Years Ago, You Would Have This Much Today
Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis - Slideshow
Roivant Soars 8% as Brepocitinib Delivers “Phenomenal Results” in Two Phase 3 Uveitis Trials
Roivant Sciences’ Brepocitinib Delivers Positive Phase III Uveitis Results
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.